Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin.

Inclusion Criteria

- Patients must have the psychological ability and general health that permits

completion of the study requirements and required follow up

- For men who are sexually active, the need for use of medically acceptable

contraception will be dictated by the primary treatment plan/protocol

- Study accrual was closed to women on 08/18/2021 and accrual is now only open to

males in order to meet accrual goals and study objectives. (11-AUG-2021)

- Male sex

- Any patients who will receive treatment with intravenous carboplatin (any AUC, any

cycle) on a National Cancer Institute (NCI)-sponsored National Clinical Trial

Network (NCTN)-, Experimental Therapeutics Clinical Trials Network (ETCTN)-, trial,

local trial, or through standard of care

- Age >= 18

- The patient or a legally authorized representative must provide study-specific

informed consent prior to study entry

Exclusion Criteria

- Treated at an institute where creatinine is not measured with an IDMS calibrated

assay

- History of allergic reactions to computed tomography (CT) contrast, iodine or

shellfish, or history of anaphylactic reaction to any food item

- Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or

have current indwelling nephrostomy tubes

- Edema beyond trace edema, because this will impact iohexol equilibration and

distribution

- Ascites (including pleural effusion) beyond trace ascites, because this will impact

iohexol equilibration and distribution

- Whole- or part-limb amputees, because this will impact iohexol equilibration and

distribution

- Inability to maintain a constant dose and schedule of anti-inflammatory agents,

diuretics, angiotensin II receptor blockers (ARB) and angiotensin converting enzyme

inhibitors (ACEi) for one week prior to study visit, as this impacts renal function.

If the patient is on a nonsteroidal anti-inflammatory drug (NSAID), diuretic, ARB or

ACEi, they are eligible as long as these agents are taken on a set schedule for 7 or

more days prior to study (and not on an "as needed" basis as that can cause

fluctuations in renal function)

- Inadequate venous access to obtain pharmacokinetic (PK) specimens

- Multinodular goiter, Graves' disease or autoimmune thyroiditis, per iohexol package

insert (hypothyroidism is allowed)